Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afimkibart - Roche

Next Previous
Search
Drug Profile

Afimkibart - Roche

Alternative Names: PF 6480605; PF-06480605; RG-6631; RO-7790121; RVT-3101

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Roche
  • Class Anti-inflammatories; Biological factors; Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis
  • Phase II Atopic dermatitis
  • Phase I Inflammatory bowel diseases; Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Apr 2025 Phase-II clinical trials in Atopic dermatitis in USA (SC) (NCT06863961)
  • 30 Mar 2025 Phase-I clinical trials in Non-alcoholic steatohepatitis in USA (IV)
  • 14 Mar 2025 Roche plans a phase II trial for Atopic dermatitis in March 2025 (SC) (NCT06863961)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top